Navigation Links
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Date:6/25/2010

at reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBe
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Feb. 16, 2012 Mylan Inc. (Nasdaq: ... ) today announced that Meridian Medical Technologies, a Pfizer ... and Sanofi-Aventis that will resolve pending patent litigation related ... epinephrine auto-injector known as e-cue™, which will be manufactured ...
... Acknowledging the importance of dedicated information management systems ... demonstrate the most recent version of its MOSAIQ® ... and Management Systems Society,s 2012 conference (HIMSS12), Feb. ... is a comprehensive OIS that centralizes traditional radiation ...
Cached Medicine Technology:Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 2Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 3Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 4Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement 5Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2
(Date:12/22/2014)... LENEXA, Kan. (PRWEB) December 22, 2014 ... it will add a subscription option to their ad ... for report writing services. Customers can sign up for ... report writing hours each month at a deeply discounted ... pricing tiers, and each has a progressively discounted rate. ...
(Date:12/22/2014)... December 22, 2014 On December 22, ... by Pastor Gordon Cashwell for an episode to celebrate ... Gordon, “Why is it so important to you that ... Cashwell replies, “We all should respect who Jesus was. ... founded on Christian beliefs. That means that on Jesus’ ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... -- A new vaccine created to fight an illness ... protect livestock and even humans from similar brain infections, ... deer from becoming infected by the incurable brain disorder ... in the Dec. 21 online edition of the journal ... mysterious infectious particles known as prions that go rogue. ...
(Date:12/22/2014)... 22, 2014 The Bob Woodruff ... having invested more than $5 million in programs ... and their families. , This includes $1.3 million ... nonprofits, helping with: veteran entrepreneurship; community impact; vocational ... for severely injured veterans. , “The needs of ...
Breaking Medicine News(10 mins):Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7
... boceprevir has been available since the middle of 2011 ... 1. In an early benefit assessment pursuant to the ... Products" (AMNOG), the German Institute for Quality and Efficiency ... whether boceprevir offers added benefit in comparison with the ...
... N.Y. Researchers at Rensselaer Polytechnic Institute have developed ... disease. The surprisingly simple process was used to make ... to Alzheimer,s disease. , The process is reported in ... Proceedings of the National Academy of Sciences ( ...
... , THURSDAY, Nov. 8 (HealthDay News) -- Women aged 40 ... do themselves more harm than good, British researchers report. ... at the Wessex Institute at the University of Southampton, said ... those who receive diagnoses that turn out to be false ...
... increased in mothers postpartum, suggesting a potential new population ... cohort study. In the joint study between ... Anglia, researchers analyzed data on all women with pregnancies ... Database, which contains records from 460 practices across the ...
... Many Americans who experience acute kidney injury that does not ... year, which suggests that doctors need to do more to ... Acute kidney injury, an abrupt or rapid decline in kidney ... is caused by medical or surgical complications that deprive the ...
... Societies for Experimental Biology (FASEB) is pleased to announce ... for Glycobiology and the Society for Pediatric Research, which ... 2012. "These are very dynamic groups representing extremely important ... them as members," said FASEB President Joseph C. LaManna, ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:Researchers design Alzheimer's antibodies 2Health News:British Study Suggests Mammograms Do More Harm Than Good 2Health News:British Study Suggests Mammograms Do More Harm Than Good 3Health News:Diagnosis of tuberculosis is increased in postpartum women 2Health News:Few With Acute Kidney Injury See Specialists, Study Finds 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
Direct antigen rapid immunoassay for the detection of Shiga toxin-producing E. coli 0157, which aids in the diagnosis of E. coli 0157:H7 infection...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Inquire...
Medicine Products: